Meta AnalysisID 8005
糖皮质激素治疗与慢性阻塞性肺疾病患者糖尿病和高血糖风险：系统评价与Meta分析
CRD42023482601
In people living with chronic obstructive pulmonary disease (COPD): 1) What is the prevalence of glucocorticoid-induced hyperglycaemia and diabetes? 2) What is the incidence of glucocorticoid-induced hyperglycaemia and d
Relationship Network
Interactive first-hop connections across herbs, ingredients, formulas, targets, diseases, symptoms, syndromes, evidence, and monographs.
Click a node to open it in a new tab
Ingredient: 1Meta-analysis: 1Links: 1
Arranging relationship network...
Record Fields
Scalar fields from the final meta_analysis record.
- Meta Analysis Id
- 8005
- Evidence Id
- 16563
- Core Evidence Id
- 16563
- Source Meta Analysis Id
- 8004
- Herb2 Meta Analysis Id
- HBMA008004
- Crd Id
- CRD42023482601
- Title
- Glucocorticoid treatment and risk of diabetes and hyperglycaemia in people living with chronic obstructive pulmonary disease: systematic review and meta-analysis
- Review Question
- In people living with chronic obstructive pulmonary disease (COPD): 1) What is the prevalence of glucocorticoid-induced hyperglycaemia and diabetes? 2) What is the incidence of glucocorticoid-induced hyperglycaemia and diabetes? 3) What is the relative risk of glucocorticoid-induced hyperglycaemia and diabetes compared to those not exposed to systemic glucocorticoids? 4) What are the characteristics of the dose-response relationship between systemic glucocorticoid use and new-onset diabetes (people without diabetes) and hyperglycaemia (people with diabetes)? 5) Do the observed associations vary according to study design, diabetes status at baseline, treatment duration and year of publication, method for ascertaining diabetes and hyperglycaemia, body mass index (BMI) and maintenance treatment for COPD?
- Study Type Included
- Inclusion: Randomised controlled trials (RCTs), single arm trials, and observational analyses of RCTs; in trials, glucocorticoid-induced diabetes/hyperglycaemia will typically be a secondary or safety outcome rather than primary outcome, cohort studies (prospective and retrospective), case-control studies (report measures other than incidence), cross-sectional studies (prevalence). Observational studies will also include pharmacoepidemiological studies of real-world data. Exclusion: Study design does not belong to any of the following categories: Single arm trials, RCTs and observational analyses of RCTs; cohort studies (prospective and retrospective), case-control studies, cross-sectional studies.
- Condition Being Studied
- In people living with COPD we will study: 1) Glucocorticoid-induced diabetes defined as a new-onset diabetes following exposure to glucocorticoids in people without pre-existing diabetes; and 2) Glucocorticoid-induced hyperglycaemia defined as worsening hyperglycaemia in people with diabetes following exposure to glucocorticoids.
- Participant
- Inclusion: Adults (aged 18 years or older) diagnosed with COPD, with or without documented diabetes mellitus at baseline documented (i.e. information on personal history of diabetes at study entry) Exclusion: Children (aged < 18 years)
- Animal
- Human Disease Modelled
- Intervention
- Inclusion: Systemic use of glucocorticoids (oral, intravenous or intramuscular administration) including dexamethasone, prednisone, prednisolone, methylprednisolone, hydrocortisone, budesonide, cortisone, deflazacort, plenadren and triamcinolone (15) equivalent to prednisolone 5 mg daily or higher for 3 or more days with or without a concomitant use of topical glucocorticoids. Exclusion: Topical use of glucocorticoids (inhaled, eye/ear drops, per rectum, intraarticular, dermal, etc.) without concomitant systemic glucocorticoids or systemic glucocorticoid treatment of less than 3 days
- Comparator Control
- People not exposed to systemic glucocorticoids
- Main Outcome
- • Diabetes mellitus (new onset in people without prior diagnosis of diabetes mellitus) as defined in each study • Hyperglycaemia (worsening glycaemic control in people with diabetes mellitus before starting glucocorticoids) as defined in each study Measures of effect Reported hazard ratios, relative risks, or odds ratios with confidence intervals
- Outcome Measure
- Additional Outcome
- Hyperglycaemia requiring new treatment (study specific definition) Measures of effect Reported hazard ratios, relative risks, or odds ratios with confidence intervals
- Study Method
- Epidemiologic, Meta-analysis, Systematic review
- Keyword
- MeSH headings have not been applied to this record
- Contact
- Rajna Golubic [email protected]
- Organisational Affiliation
- University of Oxford
- Funding Source
- No funding was available for this review
- Other Selection Criteria
- Final Publication
- Same Topic Review
- Published Protocol
- Review Type
- Language
- English
- Country
- England
- Review Stage
- Review Ongoing
- First Submission Date
- 2023-12-04
- Registration Date
- 2023-12-11
- Anticipated Start Date
- 2022-01-23
- Anticipated Completion Date
- 2024-05-31
- Title Cn
- 糖皮质激素治疗与慢性阻塞性肺疾病患者糖尿病和高血糖风险：系统评价与Meta分析
- Title En
- Glucocorticoid treatment and risk of diabetes and hyperglycaemia in people living with chronic obstructive pulmonary disease: systematic review and meta-analysis
- Bilingual Status
- complete